RS 15385-197 | CAS#119813-87-5 | alpha 2-adrenoceptor antagonist

MedKoo Cat#: 461467 | Name: RS 15385-197

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RS 15385-197 is a potent and selective alpha 2-adrenoceptor antagonist.

Chemical Structure

RS 15385-197

CAS#119813-87-5

Theoretical Analysis

MedKoo Cat#: 461467

Name: RS 15385-197

CAS#: 119813-87-5

Chemical Formula: C18H26N2O3S

Exact Mass: 350.1664

Molecular Weight: 350.47

Elemental Analysis: C, 61.69; H, 7.48; N, 7.99; O, 13.69; S, 9.15

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

RS 15385-197; RS-15385-197; RS15385-197;

IUPAC/Chemical Name

(8aR,12aS,13aS)-3-methoxy-12-(methylsulfonyl)-5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquinolino[2,1-g][1,6]naphthyridine

InChi Key

JKDBLHWERQWYKF-JLSDUUJJSA-N

InChi Code

InChI=1S/C18H26N2O3S/c1-23-15-5-6-16-13(10-15)7-9-19-12-14-4-3-8-20(24(2,21)22)17(14)11-18(16)19/h5-6,10,14,17-18H,3-4,7-9,11-12H2,1-2H3/t14-,17+,18+/m1/s1

SMILES Code

O=S(N1CCC[C@]2([H])CN(CCC3=C4C=CC(OC)=C3)[C@@]4([H])C[C@]12[H])(C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 350.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tallentire D, McRae G, Spedding M, Clark R, Vickery B. Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197). Br J Pharmacol. 1996 May;118(1):63-72. PubMed PMID: 8733577; PubMed Central PMCID: PMC1909492. 2: Brown CM, MacKinnon AC, Redfern WS, Hicks PE, Kilpatrick AT, Small C, Ramcharan M, Clague RU, Clark RD, MacFarlane CB, et al. The pharmacology of RS-15385-197, a potent and selective alpha 2-adrenoceptor antagonist. Br J Pharmacol. 1993 Feb;108(2):516-25. PubMed PMID: 8095420; PubMed Central PMCID: PMC1908001. 3: Hume SP, Hirani E, Opacka-Juffry J, Osman S, Myers R, Gunn RN, McCarron JA, Clark RD, Melichar J, Nutt DJ, Pike VW. Evaluation of [O-methyl-11C]RS-15385-197 as a positron emission tomography radioligand for central alpha2-adrenoceptors. Eur J Nucl Med. 2000 May;27(5):475-84. PubMed PMID: 10853800. 4: MacKinnon AC, Kilpatrick AT, Kenny BA, Spedding M, Brown CM. [3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification. Br J Pharmacol. 1992 Aug;106(4):1011-8. PubMed PMID: 1327384; PubMed Central PMCID: PMC1907641. 5: Redfern WS, MacKinnon AC, Brown CM, Martin AB, Kilpatrick AT, Clague RU, Spedding M. Modulation of central noradrenergic function by RS-15385-197. Br J Pharmacol. 1993 Feb;108(2):526-33. PubMed PMID: 8095421; PubMed Central PMCID: PMC1907981. 6: Spedding M, Newman-Tancredi A, Millan MJ, Dacquet C, Michel AN, Jacoby E, Vickery B, Tallentire D. Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat. Neuropharmacology. 1998 Jun;37(6):769-80. PubMed PMID: 9707291. 7: MacKinnon AC, Spedding M, Brown CM. Sodium modulation of 3H-agonist and 3H-antagonist binding to alpha 2-adrenoceptor subtypes. Br J Pharmacol. 1993 Jun;109(2):371-8. PubMed PMID: 8102928; PubMed Central PMCID: PMC2175701. 8: Redfern WS, Williams A. A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Br J Pharmacol. 1995 Oct;116(3):2081-9. PubMed PMID: 8640349; PubMed Central PMCID: PMC1908953. 9: MacKinnon AC, Stewart M, Olverman HJ, Spedding M, Brown CM. [3H]p-aminoclonidine and [3H]idazoxan label different populations of imidazoline sites on rat kidney. Eur J Pharmacol. 1993 Feb 23;232(1):79-87. PubMed PMID: 8096190. 10: Bancroft J, Munoz M, Beard M, Shapiro C. The effects of a new alpha-2 adrenoceptor antagonist on sleep and nocturnal penile tumescence in normal male volunteers and men with erectile dysfunction. Psychosom Med. 1995 Jul-Aug;57(4):345-56. PubMed PMID: 7480564. 11: Redfern WS, MacLean MR, Clague RU, McGrath JC. The role of alpha 2-adrenoceptors in the vasculature of the rat tail. Br J Pharmacol. 1995 Apr;114(8):1724-30. PubMed PMID: 7599941; PubMed Central PMCID: PMC1510371. 12: Bancroft J. Effects of alpha-2 blockade on sexual response: experimental studies with delequamine (RS15385). Int J Impot Res. 2000 Mar;12 Suppl 1:S64-69. Review. PubMed PMID: 10845766. 13: Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Lin CS, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C. Pharmacotherapy for erectile dysfunction. J Sex Med. 2004 Sep;1(2):128-40. Erratum in: J Sex Med. 2005 Jan;2(1):158. Lin, Shin [corrected to Lin, Ching-Shwun]. PubMed PMID: 16422967. 14: Munoz M, Bancroft J, Beard M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 2. The erectile response to erotic stimuli in men with erectile dysfunction, in relation to age and in comparison with normal volunteers. Psychopharmacology (Berl). 1994 Aug;115(4):471-7. PubMed PMID: 7871091. 15: Clark RD, Repke DB, Kilpatrick AT, Brown CM, MacKinnon AC, Clague RU, Spedding M. (8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist. J Med Chem. 1989 Sep;32(9):2034-6. PubMed PMID: 2570150. 16: Gonzalez MI, Patmore L, Wilson CA. Effect of delequamine (RS15385) on female sexual behaviour in the rat. Eur J Pharmacol. 1996 Sep 19;312(1):1-6. PubMed PMID: 8891572. 17: Allard J, Giuliano F. Central nervous system agents in the treatment of erectile dysfunction: how do they work? Curr Urol Rep. 2001 Dec;2(6):488-94. Review. PubMed PMID: 12084236. 18: Munoz M, Bancroft J, Turner M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 1. The erectile response to erotic stimuli in volunteers. Psychopharmacology (Berl). 1994 Aug;115(4):463-70. PubMed PMID: 7871090. 19: Kim NN, Min K, Huang YH, Goldstein I, Traish AM. Biochemical and functional characterization of alpha-adrenergic receptors in the rabbit vagina. Life Sci. 2002 Nov 1;71(24):2909-20. PubMed PMID: 12377271. 20: Saenz de Tejada I, Kim NN, Goldstein I, Traish AM. Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum. Int J Impot Res. 2000 Mar;12 Suppl 1:S20-25. Review. PubMed PMID: 10845761.